Caprion Receives FDA Fast Track Designation for Shigamabs Clinical Program
16-May-2006 -
Caprion Pharmaceuticals Inc. announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to Shigamabs, its dual antibody product being developed for the
treatment of Shigatoxin-producing bacterial infections. The Company anticipates moving Shigamabs into a pivotal ...
anemia
bacterial infections
food
+2